Ascendis Pharma A/S - American (ASND) Trades at 52-Week High

Cornelia Mascio
Settembre 24, 2017

Moreover, Wms Partners Llc has 0.52% invested in the company for 694,800 shares.

Expert analysts at Credit Suisse now has a $50 price target on Ascendis Pharma A\/S - American Depositary Shares (NASDAQ:ASND). EcoR1 Capital LLC grew its holdings in shares of Ascendis Pharma A/S by 44.5% in the second quarter. The value of the investment in Ascendis Pharma A/S - American increased from $22,722,000 to $27,385,000 a change of $4,663,000 quarter over quarter. As of the end of the quarter Janus Capital Management LLC had sold a total of 35,260 shares trimming its holdings by 5.9%.

Overall, one research analyst has assigned a Hold rating and 3 research analysts have given a Buy rating to the stock. As of quarter end Foresite Capital Management Iii, LLC had disposed of a total of 77,600 shares trimming its stake by 77.6%. Ascendis Pharma A/S has a 52-week low of $17.15 and a 52-week high of $30.57. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company's stock valued at $154,920,000 after purchasing an additional 170,700 shares in the last quarter. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company's stock. In an analyst report published on 22 September, Credit Suisse reiterated their "Outperform" rating on shares of ASND. Wedbush reaffirmed an "outperform" rating and set a $34.00 price target (down previously from $36.00) on shares of Ascendis Pharma A/S in a research note on Wednesday, May 24th. $46's average target is 34.35% above currents $34.24 stock price.

Shares of Ascendis Pharma A/S (NASDAQ ASND) traded up 23.43% during mid-day trading on Friday, hitting $34.24. Ascendis Pharma had 6 analyst reports since September 26, 2016 according to SRatingsIntel. The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $0.78 million. During the same period in the previous year, the business posted ($0.53) EPS. The firm's quarterly revenue was down 61.4% on a year-over-year basis.

COPYRIGHT VIOLATION WARNING: "Emory University Has $1.65 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)" was reported by TrueBlueTribune and is the property of of TrueBlueTribune. Specifically, Versartis Inc's (NASDAQ:VSAR) lead candidate, somavaratan, failed to achieve non-inferiority in the ITT population for the Phase 3 VELOCITY trial in Pediatric Growth Hormone Deficiency (GHD), based on higher-than-expected growth velocity for the Genotropin arm.

Ascendis is a biopharmaceutical company, which engages in the development of drug candidates. The Firm is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE